Association between body fat and sarcopenia in older adults with type 2 diabetes mellitus: A cross-sectional study

Sun, Lina; Fu, Junsheng; Mu, Zhijing; Duan, Xuejing; Chan, Piu; Xiu, Shuangling

doi:10.3389/fendo.2023.1094075

Cited by 15 publications

(9 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study identified high WWI as a significant risk factor for sarcopenia. Past research suggested that high BMI was a protective factor for sarcopenia [26][27][28][29] , while high body fat percentage was a risk factor 28,30,31 . Although these indices indicate a higher degree of obesity as they increase in value, the observed results are inconsistent.…”

Section: Discussionmentioning

confidence: 99%

The association between weight-adjusted-waist index and sarcopenia in adults: a population-based study

Zhou,

Su,

Gong

et al. 2024

Sci Rep

View full text Add to dashboard Cite

This study aims to investigate the relationship between weight-adjusted-waist index (WWI), a new body index, and sarcopenia, while also assessing the potential of WWI as a tool for screening sarcopenic patients. The cross-sectional study involved adults who possessed complete data on WWI and appendicular skeletal muscle mass from the 1999–2006 and 2011–2018 National Health and Nutrition Examination Surveys. Weighted multivariate regression and logistic regression analyses were employed to explore the independent relationship between WWI and sarcopenia. The study included 26,782 participants. The results showed that WWI demonstrated a positive correlation with sarcopenia risk. In the fully adjusted model, with each 1 unit increase in WWI, the risk of developing sarcopenia rose 14.55 times higher among males (OR: 14.55, 95% CI 12.33, 17.15) and 2.86 times higher among females (OR: 2.86, 95% CI 2.59, 3.15). The optimal cutoff values of WWI for sarcopenia were 11.26 cm/√kg for males and 11.39 cm/√kg for females. Individuals with a higher WWI have an increased risk of developing sarcopenia, and a high WWI functions as a risk factor for sarcopenia. Assessing WWI could assist in identifying individuals at risk of sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 99%

The association between weight-adjusted-waist index and sarcopenia in adults: a population-based study

Zhou,

Su,

Gong

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…We defined low physical activity as ≤5 METs by the Duke index, with the mean being lower in subjects with sarcopenia; however, in the multivariate analysis, it was not associated with the presence of sarcopenia, low muscle strength, low muscle mass, or low gait speed. Nevertheless, several studies have reported that a state of pre-frailty (OR 4.75; 95% CI 1.90-11.89; p = 0.001) [49] and low physical activity (OR 15.35; 95% CI 1.69-139.47; p = 0.015) increases the risk of sarcopenia [19,22,[24][25][26].…”

Section: Discussionmentioning

confidence: 99%

Association between Sarcopenia and Poor Glycemic Control in Older Adults with Type 2 Diabetes Mellitus

Alfaro-Alvarado,

Rosas-Barrientos,

Ocharan-Hernández

et al. 2023

Diseases

View full text Add to dashboard Cite

Background: Aging is associated with a decrease in muscle mass. Insulin resistance and hyperglycemia accelerate muscle loss, leading to a deterioration in strength, muscle mass, and physical capacity in older adults. This study was conducted to determine the association between sarcopenia and poor glycemic control in older adults with type 2 diabetes mellitus (T2D). Methods: A cross-sectional study was carried out in older adults with T2D in geriatric outpatient clinics. Sarcopenia was diagnosed as per the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. According to glycosylated hemoglobin (HbA1c) levels, participants were classified into glycemic control (HbA1c ≤ 7.5%) and poor glycemic control (HbA1c ≥ 7.5%) groups. Results: Older adults with sarcopenia were found to have poor glycemic control compared to adults without sarcopenia (62.3% vs. 47.9%, p = 0.007). Logistic regression analysis showed an association between poor glycemic control and the presence of sarcopenia (odds ratio (OR): 1.79, 95% confidence interval (CI): 1.17–2.75) and low muscle mass (OR: 1.73, 95% CI: 1.07–2.73). Conclusions: Poor glycemic control is associated with the presence of sarcopenia and low muscle mass, which highlights the need to implement better treatment strategies in order to reduce the loss of muscle mass.

show abstract

“…Amongst T2DM patients, those with incident sarcopenia have worse islet function, insufficient insulin secretion, and more significant blood glucose fluctuations than non-sarcopenic patients [33][34][35][36]. In addition, higher body fat content was associated with sarcopenia in older adults with T2DM [37].…”

Section: Type 2 Diabetes and Sarcopeniamentioning

confidence: 99%

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Rentflejsz,

Wojszel

2024

JCM

View full text Add to dashboard Cite

Sarcopenia is a chronic, progressive skeletal muscle disease characterised by low muscle strength and quantity or quality, leading to low physical performance. Patients with type 2 diabetes mellitus (T2DM) are more at risk of sarcopenia than euglycemic individuals. Because of several shared pathways between the two diseases, sarcopenia is also a risk factor for developing T2DM in older patients. Various biomarkers are under investigation as potentially valuable for sarcopenia diagnosis and treatment monitoring. Biomarkers related to sarcopenia can be divided into markers evaluating musculoskeletal status (biomarkers specific to muscle mass, markers of the neuromuscular junction, or myokines) and markers assuming causal factors (adipokines, hormones, and inflammatory markers). This paper reviews the current knowledge about how diabetes and T2DM complications affect potential sarcopenia biomarker concentrations. This review includes markers recently proposed by the expert group of the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) as those that may currently be useful in phase II and III clinical trials of sarcopenia: myostatin (MSTN); follistatin (FST); irisin; brain-derived neurotrophic factor (BDNF); procollagen type III N-terminal peptide (PIIINP; P3NP); sarcopenia index (serum creatinine to serum cystatin C ratio); adiponectin; leptin; insulin-like growth factor-1 (IGF-1); dehydroepiandrosterone sulphate (DHEAS); C-reactive protein (CRP); interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α). A better understanding of factors influencing these biomarkers’ levels, including diabetes and diabetic complications, may lead to designing future studies and implementing results in clinical practice.

show abstract

Association between body fat and sarcopenia in older adults with type 2 diabetes mellitus: A cross-sectional study

Cited by 15 publications

References 61 publications

The association between weight-adjusted-waist index and sarcopenia in adults: a population-based study

The association between weight-adjusted-waist index and sarcopenia in adults: a population-based study

Association between Sarcopenia and Poor Glycemic Control in Older Adults with Type 2 Diabetes Mellitus

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Contact Info

Product

Resources

About